Overview
EyePoint Q2 revenue falls to $5.3 mln from $9.5 mln year-over-year
Operating expenses rise to $67.6 mln due to DURAVYU trial costs
Net loss widens to $59.4 mln from $30.8 mln in prior year
Outlook
EyePoint expects cash reserves to fund operations into 2027
Company anticipates topline Phase 3 data for DURAVYU in 2026
EyePoint preparing for potential NDA filing with registration batches
Company sees DURAVYU first-to-market among sustained release treatments
Result Drivers
TRIAL COSTS - Increase in operating expenses attributed to DURAVYU Phase 3 trial costs for wet AMD
REVENUE DECLINE - Revenue decrease due to lower recognition of deferred revenue from YUTIQ product rights license
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Product Sales | $5.33 mln | ||
Q2 Net Income | -$59.43 mln | ||
Q2 Basic EPS | -$0.85 | ||
Q2 Operating Expenses | $67.56 mln | ||
Q2 Operating Income | -$62.23 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for EyePoint Pharmaceuticals Inc is $27.50, about 60.4% above its August 5 closing price of $10.89
Press Release: ID:nGNX90vZR8
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)